Latest Conference Articles

Learning From the Norwegian Experience With Biosimilars

Kelly Davio

November 16 2017

Steinar Madsen, MD, medical director of the Norwegian Medicines Agency, shared lessons learned from the Norwegian experience with biosimilars in a Wednesday talk at the SMi Biosimilars North America conference.

Mylan Head Warns of "Whisper Campaign" Against Biosimilars

Kelly Davio

November 16 2017

At a Wednesday session of the SMi Biosimilars North America conference, Chrys Kokino, MBA, head of Mylan’s global biologics commercial division, said that biosimilars can be part of improving access to and affordability of biologic therapies for patients worldwide, but also highlighted the hurdles that biosimilar developers will have to overcome as they seek to gain a foothold in the US marketplace.

Research Documents Real-World Experience With Biosimilar Infliximab, Etanercept

Jackie Syrop

November 9 2017

Three presentations at the 2017 American College of Rheumatology’s Annual Meeting in San Diego, California, covered research on the real-world treatment of rheumatology patients with originator infliximab therapy and biosimilar infliximab (CT-P13; Inflectra and Remsima) and etanercept (Benepali) therapy.

The Great Debate on Biosimilars Boils Down to Cost and Access

The Center for Biosimilars Staff

November 9 2017

“If the patient doesn’t have better access, you don’t need a biosimilar," argues Roy Fleischmann, MD.

New Online Consultation Tool Empowers Patients With Rheumatic Diseases, Study Finds

Laura Joszt

November 9 2017

Chinese researchers employed a new online consultation tool to improve disease management for patients with rheumatic diseases who travel long distances for a consultation with their rheumatologist and noted significant savings for the patients.

Research Presented on 4 Proposed Etanercept Biosimilars

Jackie Syrop

November 9 2017

Four presentations on Monday at the 2017 American College of Rheumatology’s (ACR) Annual Meeting in San Diego, California, covered research comparing reference etanercept to 4 proposed biosimilars: SB4, LBEC0101, CHS-0214, and GP2015.

BI Announces 1-Year Data on Adalimumab Biosimilar, Cyltezo

The Center for Biosimilars Staff

November 8 2017

At this week’s American College of Rheumatology 2017 Annual Meeting, Boehringer Ingelheim (BI) announced 1-year data from the VOLTAIRE-RA trial, which showed that BI’s newly approved adalimumab biosimilar (Cyltezo) showed no clinically meaningful differences in safety, efficacy, or immunogenicity from the reference adalimumab (Humira) in patients who had moderate to severe rheumatoid arthritis (RA).

New Data Support Switching to Biosimilar Rituximab in Treating RA

Kelly Davio

November 8 2017

On Tuesday, 2 research groups presented findings from studies conducted in patients with rheumatoid arthritis (RA) who were switched from reference rituximab to a biosimilar therapy.

Obese Patients With Rheumatoid Arthritis Less Likely to Achieve Remission

Laura Joszt

November 8 2017

Research presented at the 2017 American College of Rheumatology Annual Meeting found that patients with rheumatoid arthritis and higher body mass index were less likely to achieve remission and more likely to face higher rates of disability.

4 Studies Address Successes, Failures, and Strategies in Non-Medical Biosimilar Switching

Jackie Syrop

November 8 2017

Today, 4 presentations at the 2017 American College of Rheumatology’s (ACR) Annual Meeting in San Diego, California, covered research on switching studies concerning etanercept and infliximab biosimilars.